Abstract: A directed chemical conjugate of a glucagon-like peptide-2 mutant, and a use thereof are provided. The glucagon-like peptide-2 mutant is based on the human glucagon-like peptide-2 through multiple site mutations and carboxy terminus extensions. By introducing a targeted chemical modification site, the glucagon-like peptide-2 mutant has biological activities consistent with the natural human glucagon-like peptide-2, and meanwhile, the half-life period in vivo is significantly prolonged, and the administration frequency is reduced, thereby achieving the purpose of treating or preventing short intestinal syndrome, intestinal mucosa injury caused by chemotherapy medicaments or radioactive treatment factors, ulcerative enteritis, chronic enteritis and non-inflammatory bowel injury disease.

Abstract: A spoken dialog system and methods of using the system is described. A method may comprise: receiving audible human speech from a user; determining textual speech data based on the audible human speech; extracting, from the audible human speech, signal speech data that is indicative of acoustic characteristics which correspond to the textual speech data; and using the textual speech data and the signal speech data, generating a response to the audible human speech.